SIRT7 and neoplasm: In addition, the invigoration of tumor-infiltrating CD8+T cells by targeting tumorous SIRT7 and sustained PD-L1 expression can provide the cellular and molecular basis to potentiate the efficacy of anti-PD-1 immunotherapy.